Franklin Resources Inc. decreased its holdings in argenex SE (NASDAQ:ARGX – Free Report) by 8.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 237,701 shares of the company’s stock after selling 20,573 shares during the period. Franklin Resources Inc. owned about 0.38% of argenex worth $199,895,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the company. Capital World Investors grew its holdings in shares of argenex by 0.4% in the third quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after acquiring an additional 8,422 shares during the period. M&T Bank Corp grew its holdings in shares of argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after acquiring an additional 774,916 shares during the period. Wellington Management Group LLP grew its holdings in shares of argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the period. Bank of America Corp DE grew its holdings in shares of argenex by 1.9% in the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after acquiring an additional 6,259 shares during the period. Finally, Two Sigma Investments LP grew its holdings in shares of argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after acquiring an additional 250,278 shares during the period. Institutional investors own 60.32% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts recently commented on ARGX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Wells Fargo & Company lifted their price objective on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a report on Monday, June 1st. Citizens Jmp lifted their price objective on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a report on Friday, February 27th. Guggenheim lifted their price objective on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $1,019.50.
argenex Stock Performance
NASDAQ ARGX opened at $884.00 on Wednesday. The company has a market capitalization of $54.98 billion, a PE ratio of 39.36, a price-to-earnings-growth ratio of 1.35 and a beta of 0.47. The business’s fifty day moving average is $802.55 and its 200 day moving average is $812.13. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.
argenex (NASDAQ:ARGX – Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The company had revenue of $1.31 billion for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. On average, sell-side analysts forecast that argenex SE will post 26.19 EPS for the current year.
argenex Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Read More
- Five stocks we like better than argenex
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
